天演药业(苏州)有限公司

公司简介：

天演药业（苏州）有限公司坐落于美丽的独墅湖畔--生物纳米园内，周围设施便利，风景宜人。在国际抗体市场快速成长和国内外对新型抗体药物需求越来越大的背景下，公司应运而生，立足中国、面向全球，致力于将先进的信息技术和生物技术相结合，突破现有抗体技术局限性，以准确、快速、有效地控制靶向人源化抗体的生成、优化及表达为目标，开发出具有自主知识产权的智能化抗体技术及产品。

天演药业由享誉全球的投资集团富达生物制药风险基金和国际风险基金，以及药明康德风险基金共同投资。创始人兼首席执行官罗培志博士曾在美国成功创立Abmaxis公司，2006年被默克制药公司以独特的新药创新技术收购 ，罗博士被聘任为默克公司生物制药主任兼子公司首席技术长。共同创始人李革博士十几年来带领药明康德集团迅速发展，目前也是天演药业董事之一。在短短的时间内，公司已建立起了完整的计算及分子生物学实验设备与研发、管理核心团队，完成了智能化抗体技术平台的建设，并筛选出了针对多个药物靶标的创新抗体。

在公司快速增长之期，我们将以一流的研发条件和积极向上的工作氛围引进信息技术、生物技术等各方人才。期待与公司有着共同理想目标，意向于创新药物研发工作的有志之士加入我们。



公司简介（英）：
Adagene is an emerging biopharmaceutical company focused on developing novel technology based on computational biology and genetic engineering for generation and engineering of premier antibodies tailored to diagnostic and therapeutic application. The unique combination of the cutting edge informational technology and biotechnology for antibody engineering has positioned Adagene in the very front of the next generation of antibody technology for unmet biomedical needs in research, diagnostic and therapeutic applications. We are looking for self-motivated, ambitious engineers and scientists with solid training in IT and BT to develop your careers with us in a dynamic and fast-paced startup company.

Adagene is founded by two successful entrepreneurs in biopharmaceutical industry, Dr. Peter PeizhiLuo, Chairman and CEO of Adagene, who was the former director of biologics at Merck & Co., and Cofounder & Chief Technology Officer of Abmaxis Inc., a wholly owned subsidiary of Merck & Co;and Dr. Ge Li, the founder, Chairman and CEO of WuXiAppTec Co., Ltd., a NYSE-listed global biopharmaceutical company. Adagene is backed by leading life science investors in US and Asia: Fidelity Bioscience in Boston, Fidelity Growth Fund, and Wuxi AppTec Corporate Venture. The company has a team of experienced scientists, engineers, executives and advisors with entrepreneurial spirit to pioneer innovative technology and product development. Adagene is committed to building the fully integrated antibody technology as the innovation engine for generating superior antibodies to serve the needs for therapeutic antibodies with $60 billion sale in 2011.